Literature DB >> 36074252

"From Where I Stand": using multiple anchors yields different benchmarks for meaningful improvement and worsening in the rheumatoid arthritis flare questionnaire (RA-FQ).

Susan J Bartlett1,2,3, Vivian P Bykerk4, Orit Schieir5, Marie-France Valois6, Janet E Pope7, Gilles Boire8, Carol Hitchon9, Glen Hazlewood10,11, Louis Bessette12, Edward Keystone13, Carter Thorne14, Diane Tin14, Clifton O Bingham15.   

Abstract

PURPOSE: The Rheumatoid Arthritis Flare Questionnaire (RA-FQ) is a patient-reported measure of disease activity in RA. We estimated minimal and meaningful change from the perspective of RA patients, physicians, and using a disease activity index.
METHODS: Data were from 3- to 6-month visits of adults with early RA enrolled in the Canadian Early Arthritis Cohort. Participants completed the RA-FQ, the Patient Global Assessment of RA, and the Patient Global Change Impression at consecutive visits. Rheumatologists recorded joint counts and MD Global. Clinical Disease Activity Index (CDAI) scores were computed. We compared mean RA-FQ change across categories using patients, physicians, and CDAI anchors.
RESULTS: The 808 adults were mostly white (84%) women (71%) with a mean age of 55 and moderate-high disease activity (85%) at enrollment. At V2, 79% of patients classified their RA as changed; 59% were better and 20% were worse. Patients reporting they were a lot worse had a mean RA-FQ increase of 8.9 points, whereas those who were a lot better had a -6.0 decrease. Minimal worsening and improvement were associated with a mean 4.7 and - 1.8 change in RA-FQ, respectively, while patients rating their RA unchanged had stable scores. Physician and CDAI classified more patients as worse than patients, and minimal and meaningful RA-FQ thresholds differed by group.
CONCLUSION: Thresholds to identify meaningful change vary by anchor used. These data offer new evidence demonstrating robust psychometric properties of the RA-FQ and offer guidance about improvement or worsening, supporting its use in RA care, research, and decision-making.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Flare; Minimally important differences; Patient-reported outcomes; Rheumatoid arthritis

Year:  2022        PMID: 36074252     DOI: 10.1007/s11136-022-03227-7

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   3.440


  32 in total

1.  Comparative effectiveness research (CER): a summary of AHRQ's CER on therapies for rheumatoid arthritis.

Authors:  Gary M Oderda; Lisa M Balfe
Journal:  J Manag Care Pharm       Date:  2011 Nov-Dec

Review 2.  Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality.

Authors:  Elena Myasoedova; John M Davis; Cynthia S Crowson; Sherine E Gabriel
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

3.  The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease.

Authors:  Elena Myasoedova; Arun Chandran; Birkan Ilhan; Brittny T Major; C John Michet; Eric L Matteson; Cynthia S Crowson
Journal:  Ann Rheum Dis       Date:  2015-01-30       Impact factor: 19.103

Review 4.  The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.

Authors:  D Aletaha; J Smolen
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

5.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

6.  Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007.

Authors:  Elena Myasoedova; Cynthia S Crowson; Hilal Maradit Kremers; Terry M Therneau; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2010-06

7.  Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative.

Authors:  L Gossec; M Dougados; N Rincheval; A Balanescu; D T Boumpas; S Canadelo; L Carmona; J-P Daurès; M de Wit; B A C Dijkmans; M Englbrecht; Z Gunendi; T Heiberg; J R Kirwan; E M Mola; M Matucci-Cerinic; K Otsa; G Schett; T Sokka; G A Wells; G J Aanerud; A Celano; A Dudkin; C Hernandez; K Koutsogianni; F N Akca; A-M Petre; P Richards; M Scholte-Voshaar; G Von Krause; T K Kvien
Journal:  Ann Rheum Dis       Date:  2008-12-03       Impact factor: 19.103

8.  Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group).

Authors:  Clifton O Bingham; Christoph Pohl; Thasia G Woodworth; Sarah E Hewlett; James E May; Mahboob U Rahman; James P Witter; Daniel E Furst; C Vibeke Strand; Maarten Boers; Rieke E Alten
Journal:  J Rheumatol       Date:  2009-08-14       Impact factor: 4.666

9.  Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus.

Authors:  Susan J Bartlett; Sarah Hewlett; Clifton O Bingham; Thasia G Woodworth; Rieke Alten; Christoph Pohl; Ernest H Choy; Tessa Sanderson; Annelies Boonen; Vivian Bykerk; Amye L Leong; Vibeke Strand; Daniel E Furst; Robin Christensen
Journal:  Ann Rheum Dis       Date:  2012-07-06       Impact factor: 19.103

Review 10.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Authors:  Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2015-05-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.